Neurofibromatosis Therapeutic Acceleration Program (NTAP) partners with key stakeholders in neurofibromatosis type 1 (NF1)-associated plexiform neurofibroma (pNF) and cutaneous neurofibroma (cNF) research to ensure our efforts are directed to where they can have the greatest impact.

We work with an international community of NF1 and non-NF1 researchers, as well as industry and regulatory partners, to challenge assumptions inherent to traditional approaches for this disease and encourage the development of innovative strategies to treat pNFs and cNFs.

NTAP seeks creative partnering options that will advance pNF and cNF therapeutic development. For further information about collaborative opportunities at NTAP, please contact us at